Open-Angle Glaucoma
Nearly 70% of glaucoma patients reduced eye drop use after SLT
Selective laser trabeculoplasty effectively reduced IOP, as well as the quantity of eye drops used after treatment, among patients with open-angle glaucoma, according to research conducted in Brazil and published in the Journal of Glaucoma.
Qlaris raises $24 million for development of IOP-lowering therapy
Qlaris Bio raised $24 million during series B financing for the clinical development of QLS-111, a new IOP-lowering drug candidate for patients with glaucoma, the company announced in a press release.
Sustained-release bimatoprost implant shows safety, efficacy in early study
BOSTON — A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting.
VIDEO: iDose TR launches, receives permanent J-code
BOSTON — In this Healio Video Perspective from the ASCRS meeting, Cody McKenzie of Glaukos discusses the anticipated impact of the iDose TR, which launched during the meeting.
Qlaris Bio initiates trials for potassium channel modulator therapy in glaucoma patients
Qlaris Bio announced the initiation and dosing of two phase 2 trials aimed at assessing QLS-111, a therapy for lowering intraocular pressure by targeting episcleral venous pressure, or EVP, in patients with glaucoma.
First patient screened in phase 3b trial of IOP-lowering eye drop
Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension.
FDA approves iDose TR for glaucoma, ocular hypertension
The FDA approved the iDose TR for the lowering of IOP in patients with ocular hypertension or open-angle glaucoma, according to a press release from Glaukos.
Abstaining from alcohol may lower risk for severe visual impairment, blindness in glaucoma
Patients with open-angle glaucoma who abstain from consuming alcohol may be at lower risk for severe visual impairment and blindness, according to a review published in JAMA Network Open.
VIDEO: ONL1204 demonstrates promising results in geographic atrophy
NEW YORK — In this Healio Video Perspective from OSN New York’s Disruptive Innovations Symposium, David Esposito, CEO of ONL Therapeutics, discusses results of ONL1204 in geographic atrophy.
SLT effective, safe as long-term treatment option for open-angle glaucoma
Selective laser trabeculoplasty can safely and effectively be used as primary intervention for treatment of open-angle glaucoma or as replacement for medications, according to a report by the American Academy of Ophthalmology.